clinical trial · NCT06431607
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
GlaxoSmithKline·phase2·completed·n = 845
Influenza, HumanF2G22B/DL001ZF2H23D/DL001Z-NHF2H23B/DL001Z-NHF2H23H/DL001ZFDQ23A-NH (Flu D-QIV)GSK5800544AFlu D-TIVF2H23A/DL001Z-NH
brief summary
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
started
May 23, 2024
primary completion
Dec 27, 2024
completion
Jun 4, 2025
last updated
Mar 10, 2026
official title
A Phase 2a Randomized, Observer-blind, Dose-finding Study to Evaluate the Immunogenicity and Safety of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol